Journal article

REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer

Katrin M Sjoquist, David Espinoza, Linda Mileshkin, Sumitra Ananda, Catherine Shannon, Sonia Yip, Jeffrey Goh, David Bowtell, Michelle Harrison, Michael L Friedlander

Gynecologic Oncology | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2021


BACKGROUND: The primary aim of this study was to evaluate the activity of intraperitoneal bevacizumab (IP-bev) in delaying re-accumulation of malignant ascites in women with chemotherapy-resistant epithelial ovarian cancer (CR-EOC) who have ceased chemotherapy. Secondary outcomes were safety and quality of life. METHODS: Women with CR-EOC and malignant ascites that reaccumulated within 28 days of their last paracentesis (P-1) were administered IP-bev 5 mg/kg following their first therapeutic paracentesis on study (P0). Additional doses of IP-bev were allowed at each subsequent paracentesis (P1, P2, etc) provided the interval from the last dose was 42 days or greater (median time from first t..

View full abstract


Awarded by Cancer Australia

Funding Acknowledgements

The trial was supported by grant funding from Cancer Australia (1067589, 1050134) and the Ovarian Cancer Research Foundation. The investigators would like to thank all participants and their families for their support of the study.